Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with 5-FU and Leucovorin in Refractory Metastatic Colorectal Cancer
NCT00942266Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jul 2009
- Primary completion
- May 2011
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vorinostat in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Disease Control Rate at 2 months. Started Jul 2009; status: completed.
02
Drugs
vorinostat
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00942266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00942266.